Richard P Tobin
Overview
Explore the profile of Richard P Tobin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turner J, Van Gulick R, Robinson W, Mughal T, Tobin R, MacBeth M, et al.
Int J Cancer
. 2024 Jul;
155(10):1792-1807.
PMID: 39001563
Despite advancements in treating cutaneous melanoma, patients with acral and mucosal (A/M) melanomas still have limited therapeutic options and poor prognoses. We analyzed 156 melanomas (101 cutaneous, 28 acral, and...
2.
Iannucci J, Dominy R, Bandopadhyay S, Arthur E, Noarbe B, Jullienne A, et al.
J Neuroinflammation
. 2024 Jun;
21(1):165.
PMID: 38937750
Background: Traumatic brain injury (TBI) is a significant risk factor for Alzheimer's disease (AD), and accumulating evidence supports a role for adaptive immune B and T cells in both TBI...
3.
Mukherjee N, Katsnelson E, Brunetti T, Michel K, Couts K, Lambert K, et al.
Cell Death Dis
. 2024 Mar;
15(3):198.
PMID: 38459020
Immune checkpoint inhibitors (ICIs) are now the first-line treatment for patients with advanced melanoma. Despite promising clinical results, many patients fail to respond to these therapies. BH3 mimetics, a novel...
4.
Katsnelson E, Spengler A, Domenico J, Couts K, Loh L, Gapin L, et al.
J Leukoc Biol
. 2023 Oct;
115(1):36-46.
PMID: 37837379
Unconventional T cells represent a promising therapeutic agent to overcome the current limitations of immunotherapies due to their universal T-cell receptors, ability to respond directly to cytokine stimulation, and capacity...
5.
Palmer W, Leaton L, Campos Codo A, Crute B, Roest J, Zhu S, et al.
Sci Immunol
. 2023 Jun;
8(84):eade5343.
PMID: 37390222
Most human killer cell immunoglobulin-like receptors (KIR) are expressed by natural killer (NK) cells and recognize HLA class I molecules as ligands. KIR3DL3 is a conserved but polymorphic inhibitory KIR...
6.
Turner J, Fredrickson M, DAntonio M, Katsnelson E, Macbeth M, Van Gulick R, et al.
Nat Commun
. 2023 Jun;
14(1):3214.
PMID: 37270644
Lysophosphatidic acid (LPA) is a bioactive lipid which increases in concentration locally and systemically across different cancer types. Yet, the exact mechanism(s) of how LPA affects CD8 T cell immunosurveillance...
7.
Tobin R, Cogswell D, Cates V, Davis D, Borgers J, Van Gulick R, et al.
Clin Cancer Res
. 2022 Nov;
29(7):1209-1219.
PMID: 36378549
Purpose: A phase Ib/II clinical trial was conducted to evaluate the safety and efficacy of the combination of all-trans retinoic acid (ATRA) with pembrolizumab in patients with stage IV melanoma....
8.
Newell-Rogers M, Duong A, Nazarali R, Tobin R, Rogers S, Shapiro L
Int J Mol Sci
. 2022 Sep;
23(17).
PMID: 36077246
TBI induces splenic B and T cell expansion that contributes to neuroinflammation and neurodegeneration. The vagus nerve, the longest of the cranial nerves, is the predominant parasympathetic pathway allowing the...
9.
Turner J, Paton E, Van Gulick R, Stefanoni D, Cendali F, Reisz J, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565240
There is increasing evidence that oxidative metabolism and fatty acids play an important role in BRAF-driven tumorigenesis, yet the effect of mutation and expression on metabolism is poorly understood. We...
10.
Vorwald V, Davis D, Van Gulick R, Torphy R, Borgers J, Klarquist J, et al.
Clin Transl Immunology
. 2022 Jan;
11(1):e1367.
PMID: 35028137
Objectives: While much of the research concerning factors associated with responses to immune checkpoint inhibitors (ICIs) has focussed on the contributions of conventional peptide-specific T cells, the role of unconventional...